Achieving Global First Enrollment in Hematology: A Testament to Profound’s Mission and Values

At Profound Research, our mission is clear: Improving lives by providing advanced therapeutic options. That mission came to life in a powerful way when we recently enrolled the first patient globally in a hematology clinical trial. This milestone reflects our commitment to timely, coordinated action on behalf of patients, physicians, and sponsors.

The opportunity began when our site identified a potentially qualified patient prior to full site activation. We immediately notified the sponsor, even as final documentation and site readiness steps were still being completed. Rather than wait, our team collaborated closely with the sponsor to accelerate remaining requirements and streamline the activation process.

Within just four days of sponsor notification, Greenlight was achieved. The patient was promptly screened, received a bone marrow biopsy, and became the first person enrolled worldwide in the study.

This milestone highlights what makes Profound unique. Our vision is to create the absolute best patient-physician experience in clinical research, and that starts with meeting patients where they already receive care in trusted, community-based medical practices. It also means living out our core values every day:

• Compassion, by keeping the patient experience central
• Urgency, by acting swiftly to reduce delays in care access
• Solution Orientation, by collaborating to move past process barriers
• Excellence, by maintaining high standards in every study we support

We’re proud of this achievement not simply because we were first, but because it reflects our purpose. At Profound, we are driven to open doors for patients, accelerate access to breakthrough therapies, and deliver on our promise to be a trusted partner in clinical research.

It’s not just about moving fast. It’s about moving forward.